Developing high-affinity nanobodies to tumor-associated glycan antigens
Award amount
$149,938Program and phase
SBIR · Phase IAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- VITAN-BIOTECH LLC
- Proposal award date
- 2019-08-01
- Contract end date
- 2020-07-31
- UEI
- ML5NLF9L1FP9
- Solicitation number
- PA16-157
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Field-Deployable, low-Cost Point-of-Need urine test strips for mobile quantification of SUD medication drugs and their metabolites
- Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
- Plasmonic Glycan Arrays for Highly Sensitive Detection of Glycan-binding Proteins
- Development of safe and effective immunotherapeutics for treatment of opioid abuse and overdose
- High sensitive and specific Point of use lateral flow strip for on site test of cannabis intoxication
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
9 SBIR/STTR records share this UEI (2015–2024). Reported award amounts total $1,791,537. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services